Purdue Pharma L.P. competitors

I'm the chairman and CEO of Eli Lilly and Company, after holding management roles in the U.S., Canada and China, as well as running Lilly’s largest business unit. Before I joined Lilly in 1996, I worked as an account rep at IBM. I'm on the board of Adobe, and I'm chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA). I also serve on the board of the Central Indiana Corporate Partnership. I'm a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) CEO Steering Committee, The Business Council, Business Roundtable and the National Council for Expanding American Innovation (NCEAI). I serve on the Riley Children’s Foundation’s board of governors. I am a digital media spokesperson for Lilly and discuss topics related to our company, our business and the health care environment. We operate in a highly regulated environment, and only designated employees can discuss our products or pipeline. If you need information about our products or have questions or concerns, please visit these resources: https://e.lilly/guidelines

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

John Fraher is a Chief Executive Officer at Aptalis Pharma Inc, Chief Executive Officer at Eurand NV, and Board Member at Ellodi Pharmaceuticals and is based in United States. He has worked as Pres:Aptalis Pharma Technologies at Aptalis Pharma Inc, Production Manager at Fort Dodge Animal Health, and President at Aptalis Pharma Inc. John works or has worked as President:America at Eurand Pharmaceuticals Hldg. He attended University College Dublin between 1984 and 1989.

Matthew Roberts is a Chief Executive Officer at ASTELLAS PHARMA US, INC. and is based in Decatur, Georgia.

Haruo Naito is a Board Member at Eisai. He has worked as Director at Eisai, President/CEO at Eisai, and Executive Vice President at Eisai. Haruo works or has worked as CHAIRMAN at The Naiito Foundation. He attended Keio University and Northwestern University.

Vasant "Vas" Narasimhan is an American physician and the chief executive officer of Novartis (since 2018).

Mark Evenstad is a Chief Executive Officer at Upsher Smith Laboratories. He works or has worked as President at Upsher Smith Laboratories.